Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-152.52	-192.96	-108.43	-83.75	-28.17	-4.33
Depreciation & Amortization	1.44	0.94	0.47	0.03	-	-
Asset Writedown & Restructuring Costs	-	0.29	-	21.69	-	-
Loss (Gain) From Sale of Investments	-9.6	-9.18	-2.23	-	-	-
Stock-Based Compensation	23.91	28.59	16.57	2.73	0.05	0.2
Other Operating Activities	-0.09	-	-	16.63	21.12	0.9
Change in Accounts Payable	-7.05	-0.75	1.61	2.44	0.59	0.36
Change in Other Net Operating Assets	-15.47	6.55	-6.77	1.57	0.22	0.23
Operating Cash Flow	-159.28	-166.52	-98.77	-38.65	-6.2	-2.64
Capital Expenditures	-0.45	-0.51	-0.28	-0.26	-	-
Cash Acquisitions	-	-	-	1.9	-	-
Investment in Securities	42.06	101.45	-74.66	-216	-	-
Investing Cash Flow	41.62	100.94	-74.93	-214.37	-	-
Long-Term Debt Issued	-	-	-	0.45	6.13	2.95
Net Debt Issued (Repaid)	-	-	-	0.45	6.13	2.95
Issuance of Common Stock	95.72	53.33	167.77	158.88	0	0
Financing Cash Flow	122.73	53.33	167.77	323.55	6.13	2.95
Foreign Exchange Rate Adjustments	0.09	-0.01	-0.04	0.01	-	-
Net Cash Flow	5.16	-12.27	-5.97	70.55	-0.07	0.31
Free Cash Flow	-159.73	-167.04	-99.05	-38.91	-6.2	-2.64
Free Cash Flow Per Share	-2.44	-2.85	-1.89	-3.03	-3.12	-1.59
Cash Income Tax Paid	-	-	-	-	0	-
Levered Free Cash Flow	-100.83	-95.04	-58.58	-33.09	-3.77	-
Unlevered Free Cash Flow	-100.83	-95.04	-58.58	-33.03	-3.55	-
Change in Net Working Capital	21.75	-5.94	4.64	-6.44	-0.81	-

Source: S&P Capital IQ. Standard template. Financial Sources.